CA2379586A1 - Ligands fluides a cible definie - Google Patents
Ligands fluides a cible definie Download PDFInfo
- Publication number
- CA2379586A1 CA2379586A1 CA002379586A CA2379586A CA2379586A1 CA 2379586 A1 CA2379586 A1 CA 2379586A1 CA 002379586 A CA002379586 A CA 002379586A CA 2379586 A CA2379586 A CA 2379586A CA 2379586 A1 CA2379586 A1 CA 2379586A1
- Authority
- CA
- Canada
- Prior art keywords
- fluid
- binding
- ligand
- antibody
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002379586A CA2379586A1 (fr) | 2002-04-10 | 2002-04-10 | Ligands fluides a cible definie |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002379586A CA2379586A1 (fr) | 2002-04-10 | 2002-04-10 | Ligands fluides a cible definie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2379586A1 true CA2379586A1 (fr) | 2003-10-10 |
Family
ID=29220445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002379586A Abandoned CA2379586A1 (fr) | 2002-04-10 | 2002-04-10 | Ligands fluides a cible definie |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2379586A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
| US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN113215540A (zh) * | 2016-07-13 | 2021-08-06 | 住友化学株式会社 | 溅射靶及溅射靶制造用接合体 |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
-
2002
- 2002-04-10 CA CA002379586A patent/CA2379586A1/fr not_active Abandoned
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
| US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
| US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| CN113215540A (zh) * | 2016-07-13 | 2021-08-06 | 住友化学株式会社 | 溅射靶及溅射靶制造用接合体 |
| CN113215540B (zh) * | 2016-07-13 | 2023-12-08 | 住友化学株式会社 | 溅射靶及溅射靶制造用接合体 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10961317B2 (en) | CD20 scFv-ELPs methods and therapeutics | |
| US10800828B2 (en) | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer | |
| US10758556B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| JP5925875B2 (ja) | 抗体−薬剤コンジュゲート | |
| US8293243B2 (en) | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | |
| US7951614B2 (en) | Methods and compositions for the production of monoclonal antibodies | |
| US20150238631A1 (en) | Chimeric antigen receptor t cell switches and uses thereof | |
| CN109071627A (zh) | Cd8结合剂 | |
| JP2018524284A (ja) | 抗ｒｏｒ１抗体 | |
| TW202014436A (zh) | 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法 | |
| US20170081410A1 (en) | Compositions and methods for targeting a pathway | |
| JP2003501401A (ja) | Ｂ細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法 | |
| WO2019024911A1 (fr) | Conjugué anticorps anti-b7h3-médicament et son utilisation médicale | |
| JP2006526408A (ja) | 多価タンパク質複合体 | |
| HRP20220553T1 (hr) | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela | |
| Cho et al. | Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells | |
| JP2012050464A (ja) | 高い結合親和性を有する免疫結合体 | |
| WO2018133873A1 (fr) | Polypeptide ou composite liant pd-l1 | |
| US11299528B2 (en) | Long acting TRAIL receptor agonists for treatment of autoimmune diseases | |
| CA2379586A1 (fr) | Ligands fluides a cible definie | |
| CN113512117B (zh) | 一种可结合cd206的抗体及其应用 | |
| CN1078401A (zh) | 抗与表面抗原相关的cd33的免疫毒素 | |
| US20120076795A1 (en) | Anti-PECAM Therapy, Compositions, Methods, and Uses | |
| EP4135769A1 (fr) | Compositions de réorientation de cellules immunitaires et leurs utilisations thérapeutiques | |
| RU2663104C1 (ru) | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |